Harel Insurance Investments & Financial Services Ltd. Has $7.43 Million Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Harel Insurance Investments & Financial Services Ltd. boosted its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 52.8% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 54,425 shares of the company’s stock after purchasing an additional 18,797 shares during the quarter. Harel Insurance Investments & Financial Services Ltd.’s holdings in Neurocrine Biosciences were worth $7,429,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. Commerce Bank increased its position in shares of Neurocrine Biosciences by 2.6% in the third quarter. Commerce Bank now owns 4,199 shares of the company’s stock worth $484,000 after purchasing an additional 108 shares during the period. Tokio Marine Asset Management Co. Ltd. increased its holdings in Neurocrine Biosciences by 2.7% in the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 4,302 shares of the company’s stock valued at $496,000 after buying an additional 113 shares during the period. Brooklyn Investment Group raised its position in shares of Neurocrine Biosciences by 99.1% in the 4th quarter. Brooklyn Investment Group now owns 231 shares of the company’s stock valued at $32,000 after buying an additional 115 shares in the last quarter. Tealwood Asset Management Inc. lifted its holdings in shares of Neurocrine Biosciences by 1.0% during the 4th quarter. Tealwood Asset Management Inc. now owns 11,911 shares of the company’s stock worth $1,626,000 after acquiring an additional 118 shares during the period. Finally, MassMutual Private Wealth & Trust FSB boosted its position in shares of Neurocrine Biosciences by 42.0% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 531 shares of the company’s stock worth $72,000 after acquiring an additional 157 shares in the last quarter. Institutional investors own 92.59% of the company’s stock.

Insider Buying and Selling at Neurocrine Biosciences

In other news, CEO Kyle Gano sold 65,000 shares of the company’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $141.50, for a total value of $9,197,500.00. Following the sale, the chief executive officer now directly owns 135,392 shares of the company’s stock, valued at approximately $19,157,968. This represents a 32.44 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Ingrid Delaet sold 1,091 shares of the stock in a transaction on Tuesday, December 17th. The stock was sold at an average price of $135.00, for a total transaction of $147,285.00. Following the sale, the insider now owns 2,507 shares of the company’s stock, valued at approximately $338,445. This trade represents a 30.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 68,694 shares of company stock valued at $9,676,730. 4.30% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts have commented on NBIX shares. UBS Group boosted their price objective on shares of Neurocrine Biosciences from $142.00 to $162.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. Barclays boosted their price target on Neurocrine Biosciences from $160.00 to $165.00 and gave the stock an “overweight” rating in a report on Monday, December 23rd. HC Wainwright reaffirmed a “buy” rating and issued a $190.00 price objective on shares of Neurocrine Biosciences in a research note on Monday, December 16th. Needham & Company LLC reissued a “hold” rating on shares of Neurocrine Biosciences in a research note on Friday, December 20th. Finally, Piper Sandler restated an “overweight” rating and issued a $160.00 price target on shares of Neurocrine Biosciences in a research note on Monday, December 23rd. Five equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Neurocrine Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $164.81.

Neurocrine Biosciences Trading Up 0.8 %

Shares of NBIX stock opened at $148.73 on Friday. The stock has a 50-day moving average of $134.09 and a 200-day moving average of $131.46. The stock has a market cap of $15.06 billion, a price-to-earnings ratio of 39.87 and a beta of 0.33. Neurocrine Biosciences, Inc. has a 1-year low of $110.95 and a 1-year high of $157.98.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.